A multicentre observational study to investigate feasibility of a direct oral penicillin challenge in de-labelling ‘low risk’ patients with penicillin allergy by non-allergy healthcare professionals (SPACE study): Implications for healthcare systems
Journal of Infection · 2024
DOI: 10.1016/j.jinf.2024.01.015 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Infection, 2024. Verfasst von Mamidipudi Thirumala Krishna und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology and Immunotherapy, University of Birmingham and Department of Allergy and Immunology, University Hospitals Birmingham NHS Fou…. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Hypersensitivity. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, NIHR.
Abstract (Originalsprache)
OBJECTIVE: The huge burden of inaccurate penicillin allergy labels (PALs) is an important driver of antimicrobial resistance. This is magnified by insufficient allergy specialists and lack of 'point-of-care' tests. We investigated the feasibility of non-allergy healthcare professionals (HCPs) delivering direct oral penicillin challenges (DPCs) for penicillin allergy de-labelling. METHODS: This prospective observational study was conducted in three hospitals in England across three settings (acute medical, pre-surgical and haematology-oncology). Patients with a PAL were screened and stratified as low risk/high risk. Low risk patients (non-immune mediated symptoms, benign rash, tolerated amoxicillin since and family history) underwent a DPC. RESULTS: N = 2257 PALs were screened, 1054 were eligible; 643 were approached, 373 declined, 270 consented and 259 risk stratified (low risk = 155; high risk = 104). One hundred and twenty-six low risk patients underwent DPC, 122 (96.8%) were de-labelled with no serious allergic reactions. Conversion rate from screening-to-consent was 12% [3.3% and 17.9% in acute and elective settings respectively; odds ratios for consent were 3.42 (p < 0.001) and 5.53 (p < 0.001) in haematology-oncology and pre-surgical setting respectively. Common reasons for failure to progress in the study included difficulty in reaching patients, clinical instability/medical reasons, lacking capacity to consent and psychological factors. INTERPRETATION: DPCs can be delivered by non-allergy HCPs. A high proportion of patients with PALs did not progress in the study pathway. Strategies to deliver DPC at optimal points of the care pathway are needed to enhance uptake. Elective settings offer greater opportunities than acute settings for DPC. The safety and simplicity of DPCs lends itself to adoption by healthcare systems beyond the UK, including in resource-limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Immunology and Immunotherapy, University of Birmingham and Department of Allergy and Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. Electronic address: m.t.krishna@bham.ac…
- Department of Pharmacy, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Department of Pharmacy, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust and UCL School of Pharmacy, London, UK.
- Health Services Management Centre, University of Birmingham, Birmingham, UK.
- Healthcare Associated Infection Group, Leeds Institute of Medical Research, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Förderung
- Wellcome Trust
- NIHR
Zitieren
APA
Krishna, M. T., Bhogal, R., Ng, B. Y., Kildonaviciute, K., Jani, Y. H., Williams, I., Sandoe, J. A. T., Pollard, R., Jones, N., Dunsmure, L., Powell, N., Hullur, C., Balaji, A., Moriarty, C., Jackson, B., Warner, A., Daniels, R., West, R., Thomas, C., …, & Savic, L. (2024). A multicentre observational study to investigate feasibility of a direct oral penicillin challenge in de-labelling ‘low risk’ patients with penicillin allergy by non-allergy healthcare professionals (SPACE study): Implications for healthcare systems. Journal of Infection. https://doi.org/10.1016/j.jinf.2024.01.015
Vancouver
Krishna MT, Bhogal R, Ng BY, Kildonaviciute K, Jani YH, Williams I, et al. A multicentre observational study to investigate feasibility of a direct oral penicillin challenge in de-labelling ‘low risk’ patients with penicillin allergy by non-allergy healthcare professionals (SPACE study): Implications for healthcare systems. Journal of Infection. 2024. doi:10.1016/j.jinf.2024.01.015
BibTeX
@article{Krishna2024,
author = {Krishna, Mamidipudi Thirumala and Bhogal, Rashmeet and Ng, Bee Yean and Kildonaviciute, Kornelija and Jani, Yogini H and Williams, Iestyn and Sandoe, Jonathan A T and Pollard, Rachel and Jones, Nicola and Dunsmure, Louise and Powell, Neil and Hullur, Chidanand and Balaji, Ariyur and Moriarty, Catherine and Jackson, Beverley and Warner, Amena and Daniels, Ron and West, Robert and Thomas, Caroline and Misbah, Siraj A and Savic, Louise},
title = {A multicentre observational study to investigate feasibility of a direct oral penicillin challenge in de-labelling ‘low risk’ patients with penicillin allergy by non-allergy healthcare professionals (SPACE study): Implications for healthcare systems},
journal = {Journal of Infection},
year = {2024},
doi = {10.1016/j.jinf.2024.01.015}
}
EUVIMED